Recipient Outcomes After Utilization of Kidneys From Deceased Donors With Diagnosed Glioblastoma Multiforme

IF 1.9 4区医学 Q2 SURGERY Clinical Transplantation Pub Date : 2025-02-06 DOI:10.1111/ctr.70090

Venkata Kanaka Naga Karthik Nasika, Vanjinathan Subramani, Ashish Sharma, Sarbpreet Singh, Jasmine Sethi, SreeVani Paladugu, Kajal Jain, Navdeep Bansal

{"title":"Recipient Outcomes After Utilization of Kidneys From Deceased Donors With Diagnosed Glioblastoma Multiforme","authors":"Venkata Kanaka Naga Karthik Nasika, Vanjinathan Subramani, Ashish Sharma, Sarbpreet Singh, Jasmine Sethi, SreeVani Paladugu, Kajal Jain, Navdeep Bansal","doi":"10.1111/ctr.70090","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The exact incidence of donor tumor transmission in patients with glioblastoma multiforme (GBM) is still unknown. These transplants are usually considered as a high-risk endeavor due to fear of potential spread especially with medical intervention leading to breach in blood–brain barrier. This report describes successful outcomes after renal transplantation from two donors with World Health Organization (WHO) Grade IV primary GBM who had undergone surgical excision with ventriculoperitoneal shunt (VPS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Between January 2019 and June 2024, case records of organ donors where the primary cause of death was GBM were screened from the departmental database. Renal transplant patients from donors with a histopathological diagnosis GBM WHO Grade IV were included in the study. The follow-up of these recipients was recorded for tumor transmission, delayed graft function, patient and graft survival.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Only kidneys were retrieved from these donors. The donor's kidneys were transplanted to four consented recipients after taking informed consent explaining the risks. During the mean follow-up of 3 years, all four patients were alive with good graft function. Nuclear scan at 3, 6 months, and yearly thereafter showed no abnormal uptake or no evidence of donor-transmitted tumor transmission in any of these patients.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>High-grade GBM donors with no evidence of systemic spread may be considered for renal transplantation.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 2","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The exact incidence of donor tumor transmission in patients with glioblastoma multiforme (GBM) is still unknown. These transplants are usually considered as a high-risk endeavor due to fear of potential spread especially with medical intervention leading to breach in blood–brain barrier. This report describes successful outcomes after renal transplantation from two donors with World Health Organization (WHO) Grade IV primary GBM who had undergone surgical excision with ventriculoperitoneal shunt (VPS).

Methods

Between January 2019 and June 2024, case records of organ donors where the primary cause of death was GBM were screened from the departmental database. Renal transplant patients from donors with a histopathological diagnosis GBM WHO Grade IV were included in the study. The follow-up of these recipients was recorded for tumor transmission, delayed graft function, patient and graft survival.

Results

Only kidneys were retrieved from these donors. The donor's kidneys were transplanted to four consented recipients after taking informed consent explaining the risks. During the mean follow-up of 3 years, all four patients were alive with good graft function. Nuclear scan at 3, 6 months, and yearly thereafter showed no abnormal uptake or no evidence of donor-transmitted tumor transmission in any of these patients.

Conclusion

High-grade GBM donors with no evidence of systemic spread may be considered for renal transplantation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.